Recent Updates
Recently added Catalysts
TLSA Positive Sentiment Score: 65/100

Tiziana Life Sciences Announces Purchase of

Wednesday, March 22, 2023 2 min read
Key Takeaway: Tiziana Life Sciences Ltd. has announced that its Chairman and Acting CEO, Gabriele Cerrone, purchased 8,000 common shares at a price of $0.89 per share, increasing his total holdings significantly. The company, noted for developing immunotherapies via novel delivery methods, is preparing to initiate Phase 2 trials of its lead candidate, intranasal foralumab, in patients with non-active secondary progressive multiple sclerosis later this year. This innovative treatment has shown positive outcomes in prior studies, particularly in relation to inflammation modulation.

Market Sentiment Analysis

POSITIVE FACTORS

  • Chairman Gabriele Cerrone increased personal investment in the company.
  • Tiziana's lead candidate, intranasal foralumab, has shown a favorable safety profile.
  • Upcoming Phase 2 trials for intranasal foralumab offer potential new treatments for SPMS.

Full Press Release Details

Tiziana Life Sciences Announces Purchase of
Common Shares by Chairman and Acting CEO
New York, March 22, 2023 - Tiziana
Life Sciences Ltd. (Nasdaq: TLSA) ("Tiziana" or the "Company"), a biotechnology company enabling breakthrough
immunotherapies via novel routes of drug delivery, today announces that it has been notified that Gabriele Cerrone, its Chairman and Acting
Chief Executive Officer, purchased 8,000 common shares at $0.89 per share, bringing his total holding to 38,701,237 common shares.
Activated T cells play an important role in the
inflammatory process. Foralumab, the only fully human anti-CD3 monoclonal antibody (mAb), binds to the T cell receptor, dampens inflammation
by modulating T cell function, thereby suppressing effector features in multiple immune cell subsets, an effect demonstrated in patients
with COVID and with multiple sclerosis, as well as in healthy normal subjects. Intranasal foralumab Phase 2 trials are expected to start
in Q3 2023 in patients with non-active SPMS. Immunomodulation by nasal anti-CD3 mAb represents a novel avenue for treatment of inflammatory
About Tiziana Life Sciences
Tiziana Life Sciences is a clinical-stage
biopharmaceutical company developing breakthrough therapies using transformational drug delivery technologies to enable alternative routes
of immunotherapy. Tiziana's innovative nasal, oral and inhalation approaches in development have the potential to provide an improvement
in efficacy as well as safety and tolerability compared to intravenous (IV) delivery. Tiziana's lead candidate, intranasal foralumab,
the only fully human anti-CD3 mAb, has demonstrated a favorable safety profile and clinical response in patients in studies to date. Tiziana's
technology for alternative routes of immunotherapy has been patented with several applications pending and is expected to allow for broad
pipeline applications.
For further inquiries:
Tiziana Life Sciences Ltd
Paul Spencer, Business Development and Investor Relations
+44 (0) 207 495 2379
info@tizianalifesciences.com
LifeSci Advisors, LLC
ikoffler@lifesciadvisors.com

Frequently Asked Questions

Who purchased shares in Tiziana Life Sciences?

Gabriele Cerrone, the Chairman and Acting CEO, purchased the shares.

How many shares did Gabriele Cerrone buy?

He purchased 8,000 common shares, increasing his total to 38,701,237 shares.

What is foralumab's role in immunotherapy?

Foralumab modulates T cell function to reduce inflammation in various conditions.

When will foralumab Phase 2 trials begin?

The Phase 2 trials for foralumab are expected to start in Q3 2023.

What are Tiziana's drug delivery technologies?

Tiziana utilizes nasal, oral, and inhalation methods for drug delivery.

Tags: TLSA Viatris Investor Conferences Healthcare Tiziana Life Sciences foralumab immunotherapy SPMS
Last updated: Mar 22, 2023